Healthcare -
Drug Manufacturers - Specialty & Generic - NASDAQ - IS
$ 9.19
2.91 %
$ 2.77 B
Market Cap
24.84
P/E
1. INTRINSIC VALUE
Balance Sheet
Alvotech
| Current Assets | 455 M |
| Cash & Short-Term Investments | 51.4 M |
| Receivables | 252 M |
| Other Current Assets | 152 M |
| Non-Current Assets | 766 M |
| Long-Term Investments | 22.7 M |
| PP&E | 410 M |
| Other Non-Current Assets | 334 M |
| Current Liabilities | 193 M |
| Accounts Payable | 67.1 M |
| Short-Term Debt | 42.2 M |
| Other Current Liabilities | 84.1 M |
| Non-Current Liabilities | 1.44 B |
| Long-Term Debt | 1.15 B |
| Other Non-Current Liabilities | 293 M |
EFFICIENCY
Earnings Waterfall
Alvotech
| Revenue | 490 M |
| Cost Of Revenue | 185 M |
| Gross Profit | 304 M |
| Operating Expenses | 235 M |
| Operating Income | 69.6 M |
| Other Expenses | 302 M |
| Net Income | -232 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Alvotech
| Net Income | -232 M |
| Depreciation & Amortization | 31.3 M |
| Capital Expenditures | -57 M |
| Stock-Based Compensation | 7.63 M |
| Change in Working Capital | -289 M |
| Others | 156 M |
| Free Cash Flow | -294 M |
Wall Street Analysts Price Targets
Alvotech
Wall Street analysts predict an average 1-year price target for ALVO of $17.2 , with forecasts ranging from
a
low of
$10 to a high of $22 .
ALVO Lowest Price Target
Wall Street Target
10 USD
8.81%
ALVO Average Price Target
Wall Street Target
17.2 USD
87.70%
ALVO Highest Price Target
Wall Street Target
22 USD
139.39%
4. DIVIDEND
ANALYSIS
ALVO does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Alvotech
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Notification for the purposes of article 13 of the Luxembourg law of 11 January 2008 on transparency requirements for issuers
Luxembourg (July 3, 2025) – Alvotech S.A. announces that on June 25, 2025, the proportion of own shares held by Alvotech S.A. reached 6.73%, crossing above the 5% threshold of the total number of voting rights. The above percentage has been calculated on the basis of 22,484,087 own shares out of 334,038,147 shares in issue to which voting rights are attached.
globenewswire.com
- 2 weeks ago
Granting of Stock Options and Vesting of Restricted Share Units
In accordance with the Remuneration Policy of Alvotech (the “Company”), which was approved at the Company's Annual General Meeting (“AGM”) on June 6, 2023, at the 2025 AGM held on June 25, 2025, four independent board directors each received a stock option grant allowing the purchase of up to 24,784 Alvotech shares.
globenewswire.com
- 2 weeks ago
Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia® (certolizumab pegol)
REYKJAVIK, Iceland and LONDON, July 01, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the companies have entered into a supply and commercialization agreement for AVT10, Alvotech's biosimilar candidate to Cimzia® (certolizumab pegol).
globenewswire.com
- 2 weeks ago
Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia® (certolizumab pegol)
REYKJAVIK, ICELAND and LONDON, UK (July 1, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the companies have entered into a supply and commercialization agreement for AVT10, Alvotech's biosimilar candidate to Cimzia® (certolizumab pegol).
globenewswire.com
- 2 weeks ago
Alvotech's Lenders Lower Interest on Senior Secured Term Loan Facility
REYKJAVIK, ICELAND (June 26, 2025) — Alvotech (NASDAQ: ALVO, ALVO SDB, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that its lenders under the Company's existing senior secured term loan facility, including GoldenTree Asset Management (collectively, the “Lenders”), have agreed to reduce the rate of interest on its existing senior secured term loan facility (the “Facility”). The agreement will lower Alvotech's interest payments in the first 12 months by an estimated US$8.2 million. This is an outcome of Alvotech's sustained operational improvements and strengthened financial performance over the past year.
globenewswire.com
- 3 weeks ago
Alvotech's Lenders Lower Interest on Senior Secured Term Loan Facility
Lenders have reduced the rate of interest on Alvotech's loan facility reflecting sustained operational improvements and strengthened financial performance
globenewswire.com
- 3 weeks ago
Main Results of 2025 Annual and Extraordinary General Meeting
REYKJAVÍK, Iceland and LUXEMBOURG, June 25, 2025 (GLOBE NEWSWIRE) -- The 2025 Annual and Extraordinary General Meeting (the "2025 AGM") of Alvotech (the "Company") was held on June 25, 2025, at Arendt House, 41A Avenue John F. Kennedy, L-2082 Luxembourg, Grand Duchy of Luxembourg.
globenewswire.com
- 3 weeks ago
Main Results of 2025 Annual and Extraordinary General Meeting
The 2025 Annual and Extraordinary General Meeting (the "2025 AGM") of Alvotech (the "Company") was held on June 25, 2025, at Arendt House, 41A Avenue John F. Kennedy, L-2082 Luxembourg, Grand Duchy of Luxembourg.
globenewswire.com
- 3 weeks ago
Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)
REYKJAVIK, ICELAND, PISCATAWAY, NEW JERSEY AND LONDON, UK (June 25, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines for patients worldwide, Kashiv Biosciences LLC (“Kashiv”), a fully integrated biopharmaceutical company headquartered in New Jersey, US, and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK-headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines, today announced positive topline results from a confirmatory efficacy study comparing AVT23 (ADL-018), a proposed biosimilar to Xolair® (omalizumab), with the reference biologic.
globenewswire.com
- 3 weeks ago
Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)
REYKJAVIK, Iceland and PISCATAWAY, N.J. and LONDON, June 25, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines for patients worldwide, Kashiv Biosciences LLC (“Kashiv”), a fully integrated biopharmaceutical company headquartered in New Jersey, US, and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK-headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines, today announced positive topline results from a confirmatory efficacy study comparing AVT23 (ADL-018), a proposed biosimilar to Xolair® (omalizumab), with the reference biologic.
globenewswire.com
- 3 weeks ago
European Medicines Agency Recommends Market Approval of AVT06, Alvotech's Proposed Biosimilar to Eylea® (aflibercept)
REYKJAVIK, Iceland and LONDON, June 23, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human use (CHMP) adopted a positive opinion recommending approval for AVT06, Alvotech's proposed biosimilar to Eylea® (aflibercept 2 mg). Based on a positive recommendation by CHMP, biosimilar medicines can be approved by the European Commission for marketing in the European Economic Area, that includes the 27 member states of the European Union, in addition to Norway, Iceland and Lichtenstein.
globenewswire.com
- 3 weeks ago
European Medicines Agency Recommends Market Approval of AVT06, Alvotech's Proposed Biosimilar to Eylea® (aflibercept)
REYKJAVIK, ICELAND and LONDON, UK (June 23, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human use (CHMP) adopted a positive opinion recommending approval for AVT06, Alvotech's proposed biosimilar to Eylea® (aflibercept 2 mg). Based on a positive recommendation by CHMP, biosimilar medicines can be approved by the European Commission for marketing in the European Economic Area, that includes the 27 member states of the European Union, in addition to Norway, Iceland and Lichtenstein.
globenewswire.com
- 3 weeks ago
8. Profile
Summary
Alvotech ALVO
COUNTRY
IS
INDUSTRY
Drug Manufacturers - Specialty & Generic
MARKET CAP
$ 2.77 B
Dividend Yield
0.00%
Description
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.
Contact
Saemundargata 15-19, Luxembourg, 102
https://www.alvotech.com
IPO
Date
June 16, 2022
Employees
1012
Officers
Mr. Anthony M. Maffia III
Chief Regulatory Affairs Officer
Mr. Faysal Kalmoua
Chief Operating Officer & Director
Mr. Giedrius Zunda
Chief Technical Officer
Ms. Tanya Zharov
General Counsel
Mr. Anil Okay
Chief Commercial Officer
Mr. Benedikt Stefansson
Vice President of Investor Relations and Global Communications
Mr. Robert Wessman
Chief Executive Officer, Founder & Executive Chairman
Mr. Joseph E. McClellan
Chief Scientific Officer
Ms. Jenny Sif Steingrimsdottir
Vice President of People & Culture
Mr. Joel Morales
Chief Financial Officer